• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FCGR2A Gene Record

  • Summary
  • Interactions
  • Claims
  • FCGR2A 2212 Druggable Genome

    Alternate Names:

    2212
    FC FRAGMENT OF IGG RECEPTOR IIA
    FCGR2A
    CD32
    CD32A
    CDw32
    FCG2
    FCGR2
    FCGR2A1
    FcGR
    IGFR2
    146790
    3616
    ENSG00000143226
    OTTHUMG00000034469
    PA28063
    BE0002098
    P12318
    Immunoglobulin gamma Fc receptor IIA
    T22212

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (2 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Wang Y et al., 2004, Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro., Angiogenesis
    Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
    Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
    Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
    Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
    Negri FV et al., 2014, Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy., Pharmacogenomics J
    Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
    Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.
    Magnes T et al., 2018, The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab., Pharmacogenomics J
    Shepshelovich D et al., 2018, Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer., Cancer Med
    Hatjiharissi et al., 2007, Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy., Clin Lymphoma Myeloma
    Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol
    Kim et al., 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood
    Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
    Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
    Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
    Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
    Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol
    Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol
    Lin et al., 2005, FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia., Blood
    Seimetz D et al., 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy., Cancer Treat Rev
  • ADALIMUMAB   FCGR2A

    Interaction Score: 1.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25823785 17139284 24667440 17016423 24048425 27044681


    Sources:
    PharmGKB

  • ABCIXIMAB   FCGR2A

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • VALZIFLOCEPT   FCGR2A

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ETANERCEPT   FCGR2A

    Interaction Score: 1.4

    Interaction Types & Directionality:
    ligand

    Interaction Info:

    PMIDs:
    15526004 27463856 19128982 15457442 24048425 27044681


    Sources:
    PharmGKB DrugBank

  • RITUXIMAB   FCGR2A

    Interaction Score: 1.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17324336 30457672 16609067


    Sources:
    PharmGKB

  • CATUMAXOMAB   FCGR2A

    Interaction Score: 1.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    20347527


    Sources:
    DrugBank

  • ALEMTUZUMAB   FCGR2A

    Interaction Score: 1.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15217834


    Sources:
    DrugBank

  • TRASTUZUMAB   FCGR2A

    Interaction Score: 1.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18347005 21109570 17139284 17704420 17016423


    Sources:
    PharmGKB

  • INFLIXIMAB   FCGR2A

    Interaction Score: 1.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25823785 24667440 24048425 27044681


    Sources:
    PharmGKB

  • DACLIZUMAB   FCGR2A

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • CETUXIMAB   FCGR2A

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23296156 27897268 17139284 17704420 17016423 28719596 30318772


    Sources:
    PharmGKB DrugBank

  • SARILUMAB   FCGR2A

    Interaction Score: 0.73

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • BEVACIZUMAB   FCGR2A

    Interaction Score: 0.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423 15886877


    Sources:
    DrugBank

  • Ensembl: ENSG00000143226

    • Version: 101_38

    Alternate Names:
    FCGR2A Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: FCGR2A

    • Version: 18-August-2020

    Alternate Names:
    PA28063 PharmGKB ID

    Gene Info:

    Publications:
    Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol
    Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol
    Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol

  • DrugBank: BE0002098

    • Version: 5.1.7

    Alternate Names:
    FCGR2A DrugBank Gene Name
    P12318 UniProt Accession
    2212 Entrez Gene Id

    Gene Info:

    Publications:
    Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
    Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
    Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine

  • HingoraniCasas: ENSG00000143226

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000143226 Gene Symbol
    FCGR2A Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: FCGR2A

    • Version: 11-November-2018

    Alternate Names:
    FCGR2A Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: Immunoglobulin gamma Fc receptor IIA

    • Version: 2020.06.01

    Alternate Names:
    FCGR2A TTD Gene Abbreviation
    T22212 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21